# Lilly tees off with Novo at ADA, GSK’s $10.6B deal, FDA reform continues in Makary’s absence

Page: https://stenobird.com/podcast/biospace-6696251/lilly-tees-off-with-novo-at-ada-gsk-s-10-6b-deal-fda-reform-continues-in-makary-s-absence
Text version: https://stenobird.com/podcast/biospace-6696251/lilly-tees-off-with-novo-at-ada-gsk-s-10-6b-deal-fda-reform-continues-in-makary-s-absence.md
Podcast: [BioSpace](https://stenobird.com/podcast/biospace-6696251)
Published: 2026-06-10T07:00:00+00:00
Episode link: https://api.riverside.com/hosting-analytics/media/9c65f8f7a7c62f8242e0a6359b50fba61045ca32c38da7df9ad4251c8df73849/eyJlcGlzb2RlSWQiOiI0ZTgyMmZkYi03OThkLTRlNDktODZkOC1jN2MzMWUwOGMxMGUiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEyODY1OWExMDBjMTVjNWJhYWJiYWUwL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTlfXzIxLTEyLTI1Lm1wMyJ9.mp3
Audio file: https://api.riverside.com/hosting-analytics/media/9c65f8f7a7c62f8242e0a6359b50fba61045ca32c38da7df9ad4251c8df73849/eyJlcGlzb2RlSWQiOiI0ZTgyMmZkYi03OThkLTRlNDktODZkOC1jN2MzMWUwOGMxMGUiLCJwb2RjYXN0SWQiOiJhMmE1MjkxNi1iZmUxLTRmMmEtYjlhMy05YmU1MDI5ZWNiZTQiLCJhY2NvdW50SWQiOiI2YTE5YWE5ZTExMTVmZWU4NGJlMjI0MTUiLCJwYXRoIjoibWVkaWEvY2xpcHMvNmEyODY1OWExMDBjMTVjNWJhYWJiYWUwL2Rhbi1zYW1vcm9kbml0c2t5cy1zdHVkaW8tYTY3azAtY29tcG9zZXItMjAyNi02LTlfXzIxLTEyLTI1Lm1wMyJ9.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/lilly-tees-off-with-novo-at-ada-gsk-s-10-6b-deal-fda-reform-continues-in-makary-s-absence
Duration seconds: 1502

## Resource

Everything came up roses for Eli Lilly at the American Diabetes Association, as the pharma boasted positive results for its new pill Foundayo and next-gen asset retatrutide —not just for weight loss but also for other indications . Obesity rival Novo Nordisk, meanwhile, held a dinner, during which executives may have convinced analysts that the company is turning a corner after a rough couple of years. Also check out ADA updates from Roche and partner Zealand Pharma, Boehringer Ingleheim , Pfizer (touting results from its Metsera buy), AstraZeneca , Kailera Therapeutics and more . Outside of ADA, the biggest news of the past week came on Tuesday with GSK striking the biggest traditional pharma/biotech M&A of the year so far with its $10.6 billion acquisition of oncology focused Nuvalent Bio. And on Monday, J&J notched a smaller deal, buying out Firefly Bio for $1B. These deals add to continued uptick in M&A seen in biopharma this year, with much of that momentum being driven by Eli Lilly and its GLP-1 cash. At an FDA listening meeting last week on the Commissioner’s National Priority Voucher program, the agency heard multiple calls to pause it . Confusion also still persists around all of the new rare disease pathways , including the new plausible mechanism framework .

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/biospace-6696251/episodes/lilly-tees-off-with-novo-at-ada-gsk-s-10-6b-deal-fda-reform-continues-in-makary-s-absence/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/biospace-6696251/lilly-tees-off-with-novo-at-ada-gsk-s-10-6b-deal-fda-reform-continues-in-makary-s-absence.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.